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Abstract
Background—Binge alcohol drinking is a particularly risky pattern of alcohol consumption that 
often precedes alcohol dependence and addiction. The transition from binge alcohol drinking to 
alcohol addiction likely involves mechanisms of synaptic plasticity and learning in the brain. The 
mitogen-activated protein kinase (MAPK) signaling cascades have been shown to be involved in 
learning and memory, as well as the response to drugs of abuse, but their role in binge alcohol 
drinking remains unclear. The present experiments were designed to determine the effects of acute 
alcohol on extracellular signaling related kinases (ERK1/2) expression and activity, and to 
determine whether ERK1/2 activity functionally regulates binge-like alcohol drinking.
Methods—Adult male C57BL/6J mice were injected with ethanol (3.0 mg/kg, IP) 10, 30 or 90 
minutes prior to brain tissue collection. Next, mice that were brought to freely consume 
unsweetened ethanol in a binge-like access procedure were pretreated with the MEK1/2 inhibitor 
SL327 or the p38 MAP kinase inhibitor SB239063.
Results—Acute ethanol increased pERK1/2 immunoreactivity relative to vehicle in brain regions 
known to be involved in drug reward and addiction, including the central amygdala and prefrontal 
cortex. However, ethanol decreased pERK1/2 immunoreactivity relative to vehicle in the nucleus 
accumbens core. SB239063 pretreatment significantly decreased ethanol consumption only at 
doses that also produced nonspecific locomotor effects. SL327 pretreatment significantly 
increased ethanol, but not sucrose, consumption without inducing generalized locomotor effects.
Conclusions—These findings indicate that ERK1/2MAPK signaling regulates binge-like 
alcohol drinking. Since alcohol increased pERK1/2 immunoreactivity relative to vehicle in brain 
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regions known to regulate drug self-administration, SL327 may have blocked this direct 
pharmacological effect of alcohol and thereby inhibited the termination of binge-like drinking.
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INTRODUCTION
Binge drinking is a particularly dangerous pattern of alcohol consumption that is strongly 
linked to increased risk of lifetime alcohol dependence (Courtney and Polich, 2009), with 
approximately 92% of excessive drinkers in the United States engaging binge drinking 
(Town et al., 2006). The National Institute of Alcohol Abuse and Alcoholism has defined a 
binge drinking episode as a level of alcohol consumption that brings blood alcohol 
concentration above 0.08 gram percent (NIAAA, 2004), which corresponds to the 
consumption of five drinks in two hours for males and four drinks in two hours for females. 
Successful development of rodent models of binge-like drinking (Rhodes et al., 2005, Thiele 
et al., 2014) has facilitated investigation of the determinants of this behavior; however, the 
neurobiological mechanisms remain to be fully characterized.
The transition from binge drinking to alcohol dependence occurs through gradual changes in 
brain structure and function over time, and likely involves alterations in synaptic plasticity 
(Kauer and Malenka, 2007). The identification of molecular targets of alcohol that play a 
role in synaptic plasticity is therefore of use to elucidate the ways in which binge alcohol 
exposure may modify brain function, and may also suggest new pharmacotherapies for 
alcoholism. The mitogen-activated protein kinase (MAPK) family of intracellular signaling 
molecules has been identified as a critical regulator of synaptic plasticity and learning in the 
brain (Thomas and Huganir, 2004). Three signaling cascades comprise the MAPK family: c-
Jun N-terminal (JNK), p38 protein kinases, and extracellular signal-regulated kinases 
(ERK1/2) (Boulton and Cobb, 1991, Robinson and Cobb, 1997, Krishna and Narang, 2008). 
All three MAPKs translocate to the nucleus upon phosphorylation, where they alter gene 
transcription (Chen et al., 1992, Roux and Blenis, 2004).
Of the three molecules, ERK1/2 has a well-established role in regulation of behavior, 
including fear learning (Maldonado et al., 2014), memory retention (Languille et al., 2009) 
and parental behaviors (Kuroda et al., 2007). ERK1/2 is expressed in brain regions that have 
been shown to be functionally involved in drug self-administration and dependence, 
including the prefrontal cortex, nucleus accumbens, amygdala and bed nucleus of the stria 
terminalis (Ortiz et al., 1995, Valjent et al., 2004). A wealth of literature has suggested that 
many drugs of abuse increase the active (phosphorylated) form of ERK1/2 in these brain 
regions, including cocaine (Lu et al., 2006), nicotine (Brunzell et al., 2003), morphine (Ortiz 
et al., 1995, Haghparast et al., 2014), d-amphetamine (Choe et al., 2002), and Δ9-
tetrahydrocannabinol (Valjent et al., 2001).
Emerging evidence indicates that ERK1/2 signaling is involved in the biochemical and 
behavioral effects of alcohol. Several studies have shown that alcohol, or alcohol-paired 
cues, alter pERK1/2 in rodent brain tissue and cell culture (Bachtell et al., 2002, Schroeder 
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et al., 2008, Pandey et al., 2008, Ibba et al., 2009, Ku et al., 2007, Hendrickson et al., 1998, 
Sanna et al., 2002, Tsuji et al., 2003, Chandler and Sutton, 2005, Kalluri and Ticku, 2002). 
Work in our lab has revealed that inhibition of ERK1/2 activation increases operant alcohol 
self-administration suggesting that ERK1/2 activity may underlie the positive reinforcing 
effects of alcohol (Faccidomo et al., 2009). However, the role of ERK1/2 signaling in binge 
alcohol drinking has not been investigated.
To address this question, we first determined the effects of acute alcohol injection on 
ERK1/2 expression and phosphorylation in the mouse brain using an immunohistochemical 
approach. By utilizing experimenter-administered ethanol, we were able to eliminate 
variability in ethanol dose. Use of immunohistochemistry allowed the brain response to 
alcohol to be resolved at the level of discrete brain regions and sub-nuclei. We also sought to 
investigate the role of ERK1/2 activation in binge-like alcohol drinking. The systemically 
active MEK1/2 inhibitor SL327 was used to inhibit downstream ERK1/2 activation. In 
addition, the p38 inhibitor SB239063 was also tested in order to determine the selectivity of 
ERK1/2 MAPK signaling in alcohol drinking behavior.
MATERIALS AND METHODS
Animals
Adult male C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine) were housed either 
four to a cage (immunohistochemistry experiments) or individually housed (behavioral 
experiments) in standard Plexiglass cages with a small PVC pipe for environmental 
enrichment. Food and water were available ad libitum in the home-cage except where noted. 
The colony room was maintained on a 12-h light/dark cycle at 21°C, and all testing occurred 
during the dark cycle. All procedures were carried out in accordance with the NIH Guide to 
Care and Use of Laboratory Animals (National Research Council, 1996) and approved by 
the Internal Review Board of the University of North Carolina, Chapel Hill.
Drugs
Ethanol for injection (20% v/v) was prepared by diluting 95% ethanol in 0.9% saline. All 
ethanol drinking solutions (v/v) were prepared by diluting 95% ethanol (Pharmco Products 
Inc., Brookfield, CT, USA) with tap water. The MEK1/2 inhibitor SL327 and the p38 
inhibitor SB239063 (Tocris Bioscience; Ellisville, MO, USA) were freshly suspended in 
45% β-cyclodextrin on the morning of each drug testing day.
Acute ethanol time course
Mice were weighed, and habituated to handling and intraperitoneal injection (saline, 0.1ml/
10g), for three days prior to the start of the experiment. On the day of the experiment, mice 
received ethanol (0 or 3 g/kg, IP) and after 10, 30, or 90 minutes were sacrificed and brains 
were rapidly removed and prepared for immunohistochemistry as described below. The 
dosage of ethanol (3 g/kg, IP) is sub-hypnotic and was chosen to be within the range of 
doses (approximately half-maximal) consumed by C57BL/6J mice in the drinking studies 
reported here.
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Tissue Preparation and Immunohistochemical Analysis
After ethanol injection, mice were anesthetized with pentobarbital and transcardially 
perfused with ice cold phosphate buffered saline (100mM) followed by 4% formaldehyde 
(pH 7.4). Brains were removed and post fixed for 48 hours at 4°C, rinsed with phosphate 
buffer. The fixed brains were stored in phosphate buffer at 4°C until sectioning. Coronal 
brain sections (40μm) were cut on a vibratome (VT1000S, Leica Microsystems, 
Bannockburn, IL) and stored in cryoprotectant at -20°C until processing for 
immunohistochemistry.
Sections were washed in PBS prior to free-floating immunohistochemical processing. 
Following pre-blocking, sections were agitated with either pERK1/2 (phospho-p44/42 
MAPK, Thr202/Tyr204) or total ERK1/2 (tERK1/2; p44/42 MAPK) antibody (Cell 
Signaling Technologies, Danvers, MA), each at a dilution of 1:400. Sections were washed 
and visualized with DAKO labeled polymer-HRP anti-rabbit secondary antibody (full 
strength) followed by DAKO DAB+ chromagen (DAKOCytomation, Carpinteria, CA). 
Sections were counterstained with toluidine blue and coverslipped with Cytoseal. Sections 
were viewed at 20-40X magnification under brightfield illumination (Olympus CX41 light 
microscope, Olympus America, Center Valley, PA). Images were acquired using a digital 
camera (Regita OEM fast, QImaging, Burnaby, BC) and immunoreactivity was quantified 
using Bioquant Life Science software (R&M Biometric, Nashville, TN). Cell counts and 
pixel measurements were divided by the area of the region and expressed as cell counts/mm2 
or pixels/mm2.
Anatomical Coordinates
Anatomical coordinates were taken from the Mouse Brain in Stereotaxic coordinates 
(Paxinos and Watson, 2001). Analyses of the nucleus accumbens and proximal brain regions 
were evaluated in coronal sections ranging from 0.86 to 1.34 mm anterior to Bregma. The 
amygdala and proximal brain regions were evaluated in coronal section ranging from -1.58 
to -2.18 mm posterior to Bregma.
Initiation of Binge Drinking
All mice were allowed seven days to acclimate to our colony facility before experimental 
manipulations began. During this time, mice received vehicle (45% w/v β-cyclodextrin, i.p.) 
habituation injections. Beginning on day 7, home-cage water bottles were removed and 
replaced with a drinking tube (10mL with double-ball bearing affixed to the wire cage lid 
with a medium binder clip) containing 20% (v/v) unsweetened ethanol (ethanol 
experiments) or 1% sucrose (SL327 control experiments). In a variation of the drinking-in-
the-dark procedure (Rhodes et al., 2005), mice had access to the solution for two hours. The 
procedure was repeated on day eight, and on day nine the ethanol access period was 
extended to a four-hour session. Ethanol volumes were recorded immediately after ethanol 
tubes were placed on the cage and at one, two and four hour time points. On the tenth day, 
the animals did not have access to ethanol, and a pattern of every-other-day four-hour binge 
ethanol access was maintained for the remainder of the experiments.
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Beginning on experimental day 17, animals were weighed and injected i.p. with either 
SB239063 (0, 1, 10, 30 mg/kg) or SL327 (0, 10, 30 mg/kg) 30 minutes prior to the drinking 
session. Animals in each experiment were dosed in a Latin-Square design with four days 
between each injection, such that one ethanol drinking day without drug pretreatment 
occurred between each drug testing day. Ethanol consumption was measured at one, two and 
four-hour intervals. In the sucrose control experiments, mice were pretreated with the lowest 
effective dose of SL327 (10 mg/kg).
Locomotor Testing
Mice were pretreated with either vehicle, 30 mg/kg SB239063 or 30 mg/kg SL327 30 
minutes prior to a one-hour (SB139063) or four-hour (SL327) locomotor activity test (n=6/
dose). Open field activity was measured in Plexiglas activity monitor chambers (27.9 cm2; 
ENV-510, Med Associates) with two sets of 16 pulse-modulated infrared photobeams 
located on opposite walls to record X–Y ambulatory movements. Distance traveled (in 
meters) throughout the session was quantified by assessing the mouse’s position in the open 
field every 100 miliseconds. Data from each chamber were collected by a computer.
Blood Alcohol Concentration
Blood alcohol levels were determined as previously described (Faccidomo et al., 2009). 
Mice were pretreated with vehicle, 30 mg/kg SB239063 or 30 mg/kg SL327 30 minutes 
prior to a 2 g/kg i.p. 20% (v/v) ethanol injection (n=6/dose) and blood alcohol concentration 
was determined from tail blood samples collected at 10, 60, 120, 180 and 240 minutes post-
injection. Immediately after the final non-drug four-hour drinking session, mice were rapidly 
decapitated and heart blood samples collected to determine blood ethanol concentration 
following a binge drinking session.
Data Analysis
For the immunohistochemistry experiments, each treatment group consisted of 8 animals. 
Measurements were taken from the left and right side of each section and 2-4 sections were 
analyzed for each brain region. Measurements from individual brain regions for each animal 
were averaged to produce a single value for a given region in each animal. As sections at 
different time points were stained separately, data were analyzed separately at each time 
point using Student’s t-test to compare saline vs. ethanol treated tissue (Graphpad Software, 
San Diego, CA).
In the behavioral experiments, data were expressed as grams of ethanol consumed or 
milliliters of sucrose solution consumed (respectively) per kilogram of body weight. One 
mouse was excluded from the SL327 data set because intake on the testing day was a 
significant outlier using Grubb’s test (p <0.05). Dose effects on ethanol consumption were 
determined using one-way repeated measures ANOVA with Student-Newman-Keuls test for 
post-hoc analysis where appropriate, whereas effects on sucrose consumption were analyzed 
via single-tailed t-test. Blood ethanol clearance data were analyzed via two-way repeated 
measures ANOVA (dose × time). Locomotor data were computed in 20 minute bins and 
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analyzed via two-way repeated measures ANOVA (dose × time). Locomotor data in the 
SL327 experiment were further analyzed for potential anxiolytic effects in an open field test. 
Thigmotaxis was evaluated by comparing distance (cm) traveled in the center zone (inner 
25% of the area) to distance traveled in the periphery (outer 75% of the area) as previously 
described (e.g.,(Hodge et al., 2002, Kash et al., 1999). Data were then analyzed in a dose × 
zone two-way repeated measures ANOVA. Alpha was set at 0.05 for all comparisons.
RESULTS
Distribution of tERK1/2 and pERK1/2 in Mouse Brain
tERK1/2 and pERK1/2 immunoreactivties were detected in numerous brain regions (Table 
1). The highest densities of tERK1/2 immunoreactivity were observed in the prefrontal 
cortex, nucleus accumbens (core and shell), bed stria terminalis, and the central amygdala. 
Moderate levels of immunostaining were observed in the cingulate, insular, and piriform 
cortices, as well as in the basolateral amygdala. The cytological pattern of tERK1/2 
immunoreactivity showed localization primarily at the plasma membrane (Fig 1). Analysis 
of tERK1/2 immunoreactivity showed no effect of ethanol treatment on tERK1/2 abundance 
in the core or shell of the nucleus accumbens, the central or basolateral amygdala, the bed 
stria terminalis, or the paraventricular nucleus of the thalamus at either 10 or 90 minutes 
(Table 1).
The highest levels of pERK1/2 immunoreactivity were observed in the prefrontal cortex, 
nucleus accumbens (core and shell), paraventricular nucleus (PVN) of the thalamus and the 
central amygdala, with lower levels of immunostaining seen in the cingulate, insular, and 
piriform cortices, and the basolateral amygdala. pERK1/2 immunoreactivity generally 
produced a heavy, punctuate pattern of staining, suggestive of nuclear localization, with 
lighter, diffuse staining within the cell body and projections (Fig 1).
Effect of Acute Ethanol on pERK1/2 Immunoreactivity
Nucleus Accumbens—The effects of acute ethanol (3g/kg) administration on pERK1/2 
immunoreactivity in nucleus accumbens were sub-regionally specific. In the core of the 
nucleus accumbens, acute ethanol reduced pERK1/2 immunoreactivity relative to vehicle 
(cell counts) in a rapid and time dependent manner (Fig 2a). pERK1/2 immunoreactivity 
was 86% lower in the nucleus accumbens core at 10 minutes [t(12) = 3.39; p<0.01] and 45% 
30 minutes [t(12) = 2.42; p <0.5] following ethanol treatment as compared to vehicle 
controls (Table 2). Representative photomicrographs illustrating the cytological pattern of 
pERK1/2 immunoreactivity in the nucleus accumbens core are shown in Figure 2b. In 
contrast, acute ethanol failed to alter pERK1/2 immunoreactivity in the shell of the nucleus 
accumbens (Fig 2c-d;p>0.05).
Amygdala—Acute ethanol (3g/kg) administration selectively increased pERK1/2 
immunoreactivity in the central but not basolateral nuclei of the amygdala as compared to 
vehicle controls. In the central amygdala, the ethanol-induced increase in ERK1/2 
phosphorylation was rapid, with a 82% increase in pERK1/2 immunoreactivity observed 10 
minutes after ethanol treatment [t(14) = 3.19, p <0.0] and increasing to 156% 30 minutes 
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after ethanol treatment [t(13) = 3.45, p <0.01; Fig 3a. In contrast, ethanol effects were not 
observed in the basolateral amygdala, although there was an insignificant trend for increases 
in pERK1/2 immunoreactivity at 90 minutes (p = 0.06) after ethanol treatment (Fig 3c). 
Representative photomicrographs illustrating the cytological pattern of pERK1/2 
immunoreactivity in the central amygdala and basolateral amygdala are shown in Figure 3, 
panels b and d.
Other Regions—Other brain regions showed time-dependent increases in pERK1/2 
immunoreactivity following acute ethanol treatment, including the bed stria terminalis and 
the PVN of the thalamus. In the PVN thalamus, pERK1/2 immunoreactivity was 
significantly elevated at 10 [t(13) = 2.85, p <0.05] and 90 [t(11) = 2.91, p <0.05] minutes 
after ethanol treatment (Table 2) compared to vehicle controls. The greatest effects of acute 
ethanol treatment were seen in the bed stria terminalis. Acute ethanol significantly increased 
pERK1/2 immunoreactivity in the region at the 10 minute time point [t(10) = 2.97, p< 0.05) 
and pERK1/2 positive cell counts were increased by 194% (Table 2). Acute ethanol 
treatment also increased pERK1/2 immunoreactivity in the medial prefrontal, cingulate, and 
piriform regions of the cortex in a time dependent manner as compared to controls (Table 4). 
Ethanol significantly increased pERK1/2 immunoreactivity in the medial prefrontal cortex at 
10 [t(10) = 3.23, p<0.01] and 30 minutes [t(12) = 4.71, p<0.001] and cingulate cortex at 30 
minutes [t(13) = 3.81, p<0.01]. In the piriform cortex, ethanol significantly increased 
pERK1/2 immunoreactivity at the 10 minute time point [t(13) = 3.35, p<0.01]. No 
significant increases in p-ERK1/2 immunoreactivity or pERK1/2-positive cell counts were 
observed in the insular cortex.
Effects of Inhibition of MAPK Siganling on Ethanol Drinking
SL327 Effects—SL327 pretreatment did not alter ethanol consumption during the first 
hour of drinking (Figure 4A). However, over the total four-hour drinking session SL327 
significantly increased ethanol consumption [main effect of Dose, F (2) = 4.26, p <0.05 
Figure 4B]. Student-Newman-Keuls test revealed that both 10 mg/kg and 30 mg/kg SL327 
significantly increased ethanol consumption compared to vehicle, p <0.05.
To test for nonselective locomotor effects, mice were pretreated with 0 or 30 mg/kg SL327 
before a four-hour locomotor activity test. Pretreatment with 30 mg/kg SL327 did not alter 
total distance traveled during the four-hour locomotor activity test (p >0.05, Figure 4C).
Blood samples collected following the last four-hour binge on a non-drug treatment day 
revealed an average blood ethanol concentration of approximately 160 mg/dL (Figure 4D). 
This value exceeds the NIAAA criteria for a binge-drinking session (80 mg/dL) (NIAAA, 
2004). SL327 (30mg/kg) failed to alter blood ethanol concentration after a 2g/kg challenge 
injection, indicating a lack of effect on blood ethanol metabolism. (p >0.05, Figure 4E).
SB239063 Effects—SB239063 pretreatment significantly reduced ethanol consumption 
during the first hour of drinking [main effect of Dose, F (3) = 10.14, p <0.001]. Student-
Newman-Keuls test indicated that the 30 mg/kg dose was significantly decreased compared 
to vehicle in the first hour of drinking, p <0.05 (Figure 5A). By the end of the drinking 
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session, the dose effect was no longer present with all doses consuming roughly equivalent 
amounts of ethanol at the four-hour time point (p >0.05, Figure 5B).
During a four-hour locomotor activity test, SB239063 pretreatment significantly decreased 
total distance traveled [t (11) = 5.61, p <0.001 Figure 5C]. SB239063 pretreatment failed to 
alter blood ethanol concentration after a 2g/kg i.p. challenge injection (p >0.05, Figure 5D).
Selectivity of SL327 Effects
To establish the selectivity of the SL327 effect for ethanol consumption, an additional 
drinking experiment was conducted using the non-drug reinforcer sucrose. The lowest 
effective dose of SL327 (10 mg/kg) was selected for comparison with vehicle. SL327 
pretreatment did not affect sucrose consumption during the first hour (Figure 6A) or over the 
entire four hour drinking period (p >0.05, Figure 6B).
To evaluate potential anxiolytic effects of SL327, locomotor data were analyzed for time 
spent in the center vs. perimeter of the chamber. A main effect of zone emerged, such that 
mice spent more time in the perimeter of the chamber than in the center zone [F(1,10) = 
504.0, p <0.0001]. No significant effect of SL327 pretreatment emerged in either zone (p 
>0.05, Figure 6C).
DISCUSSION
The neurobiological mechanisms that regulate binge alcohol drinking remain to be fully 
elucidated. Long-term adaptations in molecular brain functions driven by synaptic plasticity 
have been hypothesized to play an essential role in the establishment of pathological drug 
use (Kauer and Malenka, 2007). ERK1/2 signaling is required for synaptic plasticity and 
learning and memory (Thomas and Huganir, 2004), and therefore is of interest as a potential 
target of alcohol’s activity in the brain. The present experiments were designed to test the 
effects of alcohol on brain ERK1/2 expression and phosphorylation and determine a 
functional role for ERK1/2 activity in the regulation of binge-like alcohol drinking behavior.
Previous studies have shown that ERK1/2 activity plays a significant role in the 
pathophysiology of alcoholism (Aroor and Shukla, 2004), including acute and chronic 
responses to ethanol as well as behavioral pathologies associated with abuse such as self-
administration, withdrawal, and relapse (Faccidomo et al., 2009, Schroeder et al., 2008, 
Sanna et al., 2002, Pandey et al., 2008, Chandler and Sutton, 2005, Kalluri and Ticku, 2002). 
In an effort to further explore the effects of ethanol on ERK1/2 activation, we examined 
brain regional effects of acute ethanol exposure on ERK1/2 phosphorylation in vivo. Results 
showed that acute IP administration of ethanol (3 g/kg) produced global increases in 
ERK1/2 phosphorylation across most of the brain regions examined without altering total 
ERK1/2 immunoreactivity. At 10 and 30 minutes post-injection, ethanol (3g/kg) increased 
pERK1/2 immunoreactivity in the central amygdala and several sub-regions of the cortex. 
At 90 minutes after ethanol treatment, pERK1/2 immunoreactivity was elevated only in the 
paraventricular nuclei of the thalamus. Only the nucleus accumbens core displayed a 
reduction in pERK1/2 immunoreactivity, at 10 and 30 minutes post-injection. These results 
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indicate that ethanol alters ERK1/2 phosphorylation in a time-and brain region-dependent 
manner in the mammalian brain.
Current literature suggests that acute ethanol exposure can both increase and decrease 
ERK1/2 phosphorylation. In the majority of the brain regions examined in this study, 
pERK1/2 immunoreactivity was elevated at one or more time points after acute ethanol 
challenge. These results complement earlier findings showing ethanol-induced increases in 
ERK1/2 phosphorylation in vivo. In mice, acute ethanol exposure (2.4g/kg) increased 
pERK1/2 immunoreactivity in the Edinger-Westfal (EW) nucleus, 15 minutes after 
treatment (Bachtell et al., 2002). In rats, low dose acute ethanol treatment (1g/kg; 15 and 60 
min) produced increases in pERK1/2 immunoreactivity in the nucleus accumbens, the bed 
stria terminalis, and the amygdala (Pandey et al., 2008, Ibba et al., 2009). Additionally, 
acute ethanol exposure has also been shown to increase pERK1/2 levels in mouse 
hippocampal neurons (100 mM; 1, 3, or 6 hours of exposure) (Ku et al., 2007). Ethanol-
induced increases in ERK1/2 phosphorylation have been associated with increases in 
phosphorylation of down-stream effectors, such as Elk-1 and CREB, in the amygdala, and 
ethanol-induced increases in c-fos expression, another down-stream effector of ERK1/2, can 
be blocked by the MEK/ERK-signaling pathway inhibitor SL327 (Bachtell et al., 2002). 
These data suggest that ethanol-induced increases in pERK1/2 levels are associated with 
increased ERK1/2 activity.
There is also evidence that acute ethanol treatment may decrease ERK1/2 phosphorylation 
in the brain. Although we only found decreases in pERK1/2 immunoreactivity in the nucleus 
accumbens core, acute ethanol treatment has been shown to reduce ERK1/2 phosphorylation 
in other brain regions. In mice, acute exposure to ethanol (3.5 g/kg; 10 minutes) decreased 
pERK1/2 levels in the cerebral cortex (Kalluri and Ticku, 2002). In rats, acute ethanol 
treatment (3.5 g/kg, 60 minutes) decreased pERK1/2 levels in the cerebral cortex, as well as 
in the hippocampus and cerebellum (Chandler and Sutton, 2005). Acute ethanol exposure 
(100-150 mM; 10-60 minutes) also reduced pERK1/2 levels in cultured cortical neurons 
(Kalluri and Ticku, 2003), NG108-15 cells (Constantinescu, 2004), and SH-SY5Y cells 
(Seiler et al., 2001). Given that we found both increases and decreases in ERK1/2 
phosphorylation following acute ethanol treatment, it seems likely that the disparate findings 
in the literature are partly due to brain regional, ethanol dose and/or time-dependent 
differences in response to ethanol. Additional experiments testing lower dose ranges (1-2 
g/kg) would be useful in reconciling these disparate findings in the literature. However, it 
should be noted that the studies that found decreases in pERK1/2 immunoreactivity in the 
cortex, hippocampus, and cerebellum used western blotting methods to measure pERK1/2 
changes in large regions that are comprised of distinct subregions. By using 
immunohistochemical methods, the present study provides novel information regarding 
ethanol effects on ERK1/2 phosphorylation in specific subnuclei.
It is important to note that restraint stress has been shown to produce rapid (< 1 min) 
increases in ERK1/2 phosphorylation in the brain that dissipate by 30 min (Meller et al., 
2003). Thus, handling and injection stress could contribute to changes in pERK1/2 levels 
following acute drug injection in mice. Indeed, results suggested that the number of 
pERK1/2 positive cells decreased over time in the saline injected control groups (Table 1). 
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For this reason, all ethanol data were compared to parallel saline controls at each time point 
(10 – 90 min), which counterbalances any potential effects of injection stress across the 
measurement time points. Thus, it is not likely that injection stress significantly contributes 
to the observed increases in pERK1/2 immunoreactivity in the ethanol challenged animals. 
Alternatively, the effects of injection may be important to the decreases in pERK1/2 
immunoreactivity seen in the nucleus accumbens core following ethanol treatment. The 
relative decreases in ERK1/2 phosphorylation observed in ethanol treated animals could be 
interpreted as ethanol inhibition of injection-induced ERK1/2 phosphorylation. However, 
this does not fully account for the ethanol effect, as the pERK1/2 positive cell counts are 
significantly lower at 10 and 30 minutes (p<0.05), relative to the 90 minute time point, 
indicating a recovery of baseline pERK1/2 abundance in the ethanol treated animals. It is 
possible that ethanol injection is significantly more stressful than saline injection in these 
conditions, leading to an exaggerated response of pERK1/2 to ethanol. It will be interesting 
to determine in future experiments if self-administered ethanol, which should not produce 
acute stress effects, results in similar changes in ERK1/2 phosphorylation.
We also sought to determine the extent to which MAPK signaling was functionally involved 
in binge-like alcohol drinking behavior. Inhibition of ERK1/2 phosphorylation with the 
MEK1/2 inhibitor SL327 significantly increased home-cage alcohol drinking over the four-
hour access period without affecting open field locomotor activity. In contrast, the p38 
inhibitor SB239063 significantly decreased alcohol drinking during the first hour of intake 
at a dose that also decreased locomotor activity. These findings indicate that a reduction in 
ERK1/2 activity stimulates increased alcohol drinking under these conditions. This effect 
appears to be selective for the alcohol solution, since SL327 pretreatment did not alter 
sucrose consumption in the same access procedure.
Of the MAPK signaling pathways, the p38 signaling cascade has received relatively little 
investigation in the addiction literature. While there has been some evidence for p38 in 
morphine conditioned place preference (Zhang et al., 2012) and reinstatement of cocaine 
preference (Bruchas et al., 2011), other studies have failed to find an effect of acute cocaine 
injection on p38 expression or phosphorylation (Zhang et al., 2004, Valjent et al., 2000). In 
the present study, the p38 inhibitor SB239063 reduced ethanol drinking only at a dose that 
also induced nonspecific suppression of open-field locomotor activity. These findings do not 
support a functional role for p38 signaling in alcohol drinking.
In contrast, the MEK1/2 inhibitor SL327 selectively increased alcohol but not sucrose 
drinking without affecting locomotor behavior. This finding is consistent with previous 
work in our lab, which has demonstrated that pretreatment with SL327 increases operant 
self-administration of alcohol but not sucrose in mice (Faccidomo et al., 2009). Increased 
self-administration under either access condition can occur due to alterations in the 
motivation to consume the alcohol or blockade of the pharmacological effects of alcohol. 
Our previous work used a progressive ratio schedule of reinforcement to determine if SL327 
affected motivation to self-administer ethanol, and found that SL327 was without effect in 
this condition. Therefore, it is unlikely that SL327 is increasing the motivation to consume 
alcohol in these animals.
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Results of the present study indicate that alcohol exposure rapidly increases ERK1/2 
phosphorylation in specific brain regions. Thus, administration of the MEK1/2 inhibitor, 
which prevents ERK1/2 phosphorylation, prior to binge drinking may have antagonized the 
pharmacological activity of ethanol on ERK1/2. This would be expected to increase the 
amount of alcohol consumed in order to achieve an equivalent pharmacological effect. 
Similar results have been observed with cocaine and opiate self-administration. Antagonism 
of the primary pharmacological target of these substances (dopamine D1/D2 receptors and μ 
opioid receptors, respectively) increased drug self-administration (Woods et al., 1975, Koob 
et al., 1987). This observation may account for the increased alcohol consumption exhibited 
by mice pretreated with the MEK1/2 inhibitor SL327. The precise pharmacological effect of 
ERK1/2 activation by alcohol is not clear from the present experiments. However, the 
appearance of the SL327 effect during the later stages of testing suggests that SL327 may 
have altered the termination of alcohol drinking, such that animals treated with SL327 
continued drinking for longer during the session than vehicle treated animals. Previous 
studies have identified pharmacological manipulations that selectively alter termination of 
alcohol self-administration, including the GABA-A agonist muscimol (Hodge et al., 1995) 
and the dopamine D2-like antagonist raclopride (Hodge et al., 1994, Samson et al., 1993). 
SL327 may act similarly to extend the period of alcohol consumption by inhibiting the 
pharmacological effect of alcohol on ERK1/2 activation. This interpretation points to 
ERK1/2 activation as a potential cue for satiety or subjective intoxication. However, 
ERK1/2 inhibition in the amygdala increases the discriminative stimulus effects of a low 
dose of alcohol (Besheer et al., 2012) and is without effect in accumbens, which suggests the 
potential importance of other brain regions detected in this study such as the prefrontal 
cortex. Further evaluation of ERK1/2 activity in specific brain regions will clarify its 
potential role as a termination signal in alcohol drinking.
Alternatively, SL327 effects may be considered in the context of stress-induced alterations 
of alcohol drinking. Acute and chronic stress has been shown to alter alcohol consumption 
(Alegria et al., 2010, Lu and Richardson, 2014), and intraperitoneal injection of drug or 
vehicle prior to drinking may have been stressful in these experiments. SL327 has been 
shown to alleviate the sensitizing effect of a stressor on ethanol withdrawal-induced anxiety 
(Knapp et al., 2011). Thus, an alternative explanation for our findings is that injection stress 
reduced alcohol drinking in the vehicle condition whereas SL327 administration blocked 
this effect. However, pretreatment with SL327 failed to affect thigmotaxis in an open-field 
test suggesting lack of an anxiolytic-like effect under these conditions. Future experiments 
to directly investigate the contributions of ERK1/2 signaling to stress-induced alterations in 
alcohol drinking would clarify the findings presented here and could potentially point to an 
alternative mechanism for ERK1/2’s effects on alcohol drinking.
Immunohistochemistry experiments revealed that acute ethanol injection (3 g/kg) rapidly 
increases ERK1/2 phosphorylation in several brain regions including the nucleus 
accumbens, amygdala and prefrontal cortex. Each of these brain regions has been shown to 
regulate alcohol self-administration (Hodge et al., 1996, Hodge et al., 1992, Schroeder et al., 
2003) but use of systemically administered inhibitor in this study makes it difficult to 
identify which, if any, of these regions mediate the SL327-induced increase in alcohol 
consumption. Future experiments utilizing site-specific microinjection strategies would 
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clarify the relative contributions of ERK1/2 signaling in these nuclei to binge alcohol 
drinking.
In conclusion, our findings indicate that acute ethanol injection facilitates a general increase 
in ERK1/2 phosphorylation throughout many brain regions known to be involved in drug 
reward and addiction, such as the central and basal lateral amygdala, prefrontal cortex, and 
bed nucleus of the stria terminals. In contrast, ethanol injection resulted in decreases in 
ERK1/2 phosphorylation in the nucleus accumbens core. Systemic administration of the 
MEK1/2 inhibitor SL327 increases binge-like alcohol consumption in mice, suggesting that 
ERK1/2 activation regulates the termination of binge-like drinking.
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Figure 1. tERK1/2 and pERK1/2 immunoreactivity
Representative photomicrographs (100X) of the cytological patterns of ERK1/2 
immunoreactivity in the nucleus accumbens (a) core and (b) shell, (c) central amygdala, and 
(d) basolateral amygdala (scale bar, 10 microns).
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Figure 2. Effects of acute ethanol on ERK1/2 phosphorylation in the nucleus accumbens as a 
function of time
(A) Mean (± SEM) immunoreactivity of the pERK1/2 positive area in the nucleus 
accumbens core following 3.0 g/kg ethanol treatment expressed as relative change versus 
saline control. (B) Representative photomicrographs (20X) of the cytological pattern of 
pERK1/2 immunoreactivity in the core. (C) Mean (± SEM) immunoreactivity of the 
pERK1/2 positive area in the nucleus accumbens shell following 3.0 g/kg ethanol treatment 
expressed as relative change versus saline control. (D) Representative photomicrographs 
(20X) of the cytological pattern of pERK1/2 immunoreactivity in the shell (scale bar, 50 
microns).
*Significantly different from saline control at the given time point (p<0.05; Student’s t-test).
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Figure 3. Effects of acute ethanol on ERK1/2 phosphorylation in the amygdala as a function of 
time
(A) Mean (± SEM) immunoreactivity of the pERK1/2 positive area in the central amygdala 
following 3.0 g/kg ethanol treatment expressed as relative change versus saline control. (B) 
Representative photomicrographs of the cytological pattern of pERK1/2 immunoreactivity 
in the central amygdala. (C) Mean (± SEM) immunoreactivity of the pERK1/2 positive area 
in the basolateral amygdala following 3.0 g/kg ethanol treatment expressed as relative 
change versus saline control. (D) Representative photomicrographs of the cytological pattern 
of pERK1/2 immunoreactivity in the basolateral amygdala (scale bar, 50 microns). 
*Significantly different from saline control at the given time point (p<0.05; Student’s t-test).
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Figure 4. Systemic ERK1/2 inhibition increases binge-like ethanol intake
(A) No effect of pretreatment with the MEK1/2 inhibitor SL327 on ethanol intake emerged 
during the first hour of drinking. (B) Over the total four-hour drinking session, SL327 
significantly increased ethanol drinking at the 10 and 30 mg/kg doses. (C) Mice achieved a 
binge-level of alcohol consumption during the 4-hour testing period. (D) SL327 
pretreatment did not affect total distance traveled in a four-hour locomotor activity test. (E) 
SL327 pretreatment did not alter blood ethanol metabolism following an acute 2g/kg i.p. 
ethanol injection. *Significantly different than vehicle at the given dose (p<0.05; Student-
Newman-Keuls)
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Figure 5. Systemic p38 inhibition non-selectively decreases binge ethanol intake
(A) Pretreatment with the p38 inhibitor SB239063 (30 mg/kg) reduced ethanol intake during 
the first hour of ethanol drinking. (B) The effect was no longer present by the end of the 
four-hour drinking session. (C) Mice achieved a binge-level of alcohol consumption during 
the 4-hour testing period. (D) SB239063 pretreatment reduced total distance traveled in a 
one-hour locomotor activity test. (E) SB239063 pretreatment did not alter blood ethanol 
metabolism following an acute 2g/kg i.p. ethanol injection. *Significantly different than 
vehicle at the given dose (p<0.05; Student-Newman-Keuls)
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Figure 6. Effects of SL327 are selective for ethanol reinforcement
Mice were given access to a 1% sucrose solution on the same schedule as the ethanol 
consumption. No effect of SL327 on sucrose consumption emerged over the (A) one-hour or 
(B) four-hour access period. (C) SL327 pretreatment did not alter time spent in the center vs. 
perimeter of the open field during locomotor activity testing. *Significantly different than 
vehicle at the given dose (p<0.05; Student-Newman-Keuls)
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Table 1
Effects of acute ethanol on tERK1/2 immunoreactivity
10 minutes 90 minutes
Brain region Saline Ethanol Saline Ethanol
Nucleus Accumbens
Core 33814 ± 6981 36793 ± 25932 18723 ± 4245 11893 ± 2225
Shell 41225 ± 13501 38562 ± 24186 23204 ± 6744 18096 ± 3868
Amygdala
Central 82024 ± 27424 61740 ± 47661 22577 ± 3680 11480 ± 4376
Basolateral 20716 ± 3431 13448 ± 2405 7705 ± 881 5039 ± 1993
Bed stria terminalis 749627 ± 372334 406361 ± 235395 47070 ± 9680 46737 ± 10890
PVN Thalamus 117252 ± 37405 126097 ±78730 75072 ± 21063 30114 ± 9255
Mean number (± SEM) Mean (± SEM) immunoreactivity of the tERK1/2 positive area at 10 and 90 minutes following 3.0 g/kg ethanol treatment 
expressed as pixels/mm2.
*
Significantly different from saline control at the given time point (p<0.05; Student’s t-test).
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